Drug Patents Expiring in 2043
1. Alyftrek patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12186306 | VERTEX PHARMS INC | Methods of treatment for cystic fibrosis |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2029 |
Drugs and Companies using DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM ingredient
NCE-1 date: 20 December, 2028
Market Authorisation Date: 20 December, 2024
Treatment: Treatment of cf in patients aged 6 years and older who have at least one f508del mutation or another responsive mutation in the cftr gene with 21.4 mg of vnz calcium salt hydrate form d, 100 mg of tez...
Dosage: TABLET
More Information on Dosage
ALYFTREK family patents
2. Auvelity patent expiration
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12156914 | AXSOME | Pharmaceutical compositions comprising bupropion and cysteine |
Jan, 2043
(17 years from now) | |
| US11925636 | AXSOME | Bupropion dosage forms with reduced food and alcohol dosing effects |
Jan, 2043
(17 years from now) | |
| US11717518 | AXSOME | Bupropion dosage forms with reduced food and alcohol dosing effects |
Jan, 2043
(17 years from now) | |
| US11730706 | AXSOME | Treatment of depression in certain patient populations |
Jan, 2043
(17 years from now) | |
| US11883373 | AXSOME | Treatment of depression in certain patient populations |
Jan, 2043
(17 years from now) | |
| US12036191 | AXSOME | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
Feb, 2043
(17 years from now) | |
| US11986444 | AXSOME | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
Feb, 2043
(17 years from now) | |
| US12146889 | AXSOME | Fluorine-Containing Compound, Fluorine-Containing Polymer, Negative-Type Resist Composition, and Patterning Process Using Same |
Feb, 2043
(17 years from now) | |
| US11752144 | AXSOME | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Feb, 2043
(17 years from now) | |
| US12042473 | AXSOME | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Feb, 2043
(17 years from now) | |
| US11839612 | AXSOME | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Mar, 2043
(18 years from now) | |
| US11844797 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Apr, 2043
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder; Treatment of major depressive disorder by administering dextromethorphan and bupropion to a subject having moderate he...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AUVELITY before it's drug patent expiration?
More Information on Dosage
AUVELITY family patents
3. Brukinsa patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11911386 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11896596 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| US11786531 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-871) | Aug 31, 2024 |
| New Indication(I-874) | Sep 14, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| New Indication(I-817) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
| New Indication(I-936) | Mar 07, 2027 |
| Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
| Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
| Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
| Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with relapsed or refractory follicular lymphoma (fl) receiving a moderate cyp3a inducer, in combination with obinutuzumab, after two or more lines of systemic therapy; Trea...
Dosage: CAPSULE
More Information on Dosage
BRUKINSA family patents
4. Exparel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11918565 | PACIRA PHARMS INC | Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions |
Feb, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 28, 2014 |
| New Indication(I-771) | Apr 06, 2021 |
| New Patient Population(NPP) | Mar 22, 2024 |
| New Indication(I-929) | Nov 09, 2026 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 28 October, 2011
Treatment: A method of administering bupivacaine to produce regional analgesia via sciatic nerve block in the popliteal fossa in adults
Dosage: INJECTABLE, LIPOSOMAL
How can I launch a generic of EXPAREL before it's drug patent expiration?
More Information on Dosage
EXPAREL family patents
5. Igalmi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11806334 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jan, 2043
(17 years from now) | |
| US11998528 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jan, 2043
(17 years from now) | |
| US12138247 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jan, 2043
(17 years from now) | |
| US12090140 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual or buccal administration in patients with severe hepatic impairment; Acute treatment of agitation a...
Dosage: FILM
More Information on Dosage
IGALMI family patents
6. Ogsiveo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11925620 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11925619 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US12011434 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US12011435 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US12036207 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11872211 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US12138246 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11938116 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11957662 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11951096 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 27, 2028 |
| ODE*(ODE*) | Nov 27, 2030 |
| Orphan Drug Exclusivity(ODE-452) | Nov 27, 2030 |
Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient
NCE-1 date: 28 November, 2027
Market Authorisation Date: 27 November, 2023
Treatment: Treatment of adult patients with progressing desmoid tumors
Dosage: TABLET
More Information on Dosage
OGSIVEO family patents
7. Purified Cortrophin Gel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11975047 | ANI PHARMS | Methods for storing and warming purified corticotropin compositions |
Oct, 2043
(18 years from now) | |
| US12102662 | ANI PHARMS | Methods for storing and warming purified corticotropin compositions |
Oct, 2043
(18 years from now) | |
Drugs and Companies using CORTICOTROPIN ingredient
Market Authorisation Date: 01 January, 1982
Treatment: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus; During an exacerbation or as maintenance therapy ...
Dosage: INJECTABLE
More Information on Dosage
PURIFIED CORTROPHIN GEL family patents
8. Tarpeyo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11896719 | CALLIDITAS | Pharmaceutical compositions |
Jan, 2043
(17 years from now) | |
| US12171882 | CALLIDITAS | Pharmaceutical compositions |
Jan, 2043
(17 years from now) | |
| US12171883 | CALLIDITAS | Pharmaceutical compositions |
Jan, 2043
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2024 |
| Orphan Drug Exclusivity(ODE-389) | Dec 15, 2028 |
| Orphan Drug Exclusivity(ODE-464) | Dec 20, 2030 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 15 December, 2021
Treatment: Reduction in loss of kidney function and reduction of proteinuria in adults with primary immunoglobulin a nephropathy (igan) who are at risk of disease progression, by release of budesonide from the f...
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
TARPEYO family patents
List of large molecules
1. List of Xolair large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US12030959 | GENENTECH, INC. | Anti-IgE antibody therapy for multiple food allergies |
Jul, 2043
(18 years from now) |
Ingredients: OMALIZUMAB